NORTHWEST BIOTHERAPEUTICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NORTHWEST BIOTHERAPEUTICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.93M | Mar 5, 2024 |
| FY2023 | Dec 31, 2022 | $1.68M | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | $1.01M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $1.29M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.41M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $412.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $336.0K | Apr 2, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.38M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.93M | Mar 31, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $336.0K | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $623.0K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $1.74M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $1.45M | Mar 16, 2016 |
| FY2015 | Dec 31, 2013 | $809.0K | Mar 16, 2016 |
| FY2013 | Dec 31, 2012 | $772.0K | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | $10.0K | Apr 8, 2013 |
| FY2011 | Dec 31, 2010 | $10.0K | Apr 13, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.16M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($83.78M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($62.60M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($105.03M) | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | $179.13M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($529.82M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($20.81M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($35.79M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($73.14M) | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | ($80.21M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.91M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($66.51M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($55.51M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($67.18M) | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | ($52.70M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($86.61M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($27.98M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($41.48M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($54.68M) | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | ($79.27M) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.79M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $34.89M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $27.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $35.51M | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | $20.31M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $33.64M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $14.11M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $18.15M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $33.52M | Apr 2, 2019 |
| FY2018 | Nov 13, 2017 | $37.0K | Apr 2, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.76M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($57.02M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($53.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($52.78M) | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | ($38.30M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($32.09M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($31.86M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($34.59M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($36.50M) | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | ($55.65M) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.01M | Apr 15, 2026 |
| FY2019 | Dec 31, 2019 | $171.0K | Mar 16, 2020 |
| FY2013 | Dec 31, 2013 | ($1.0K) | Apr 1, 2014 |
| FY2013 | Dec 31, 2012 | $31.0K | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | $49.0K | Apr 8, 2013 |
| FY2011 | Dec 31, 2010 | $41.0K | Apr 13, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.29M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.73M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $27.87M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $31.32M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $40.16M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $32.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $10.64M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $24.67M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $48.91M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $52.91M | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.86M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $105.71M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $74.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $136.37M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $164.15M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $395.85M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $55.70M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $71.83M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $96.20M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $79.41M | Apr 17, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.28M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($94.49M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($65.77M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($128.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($123.99M) | Mar 5, 2024 |
| FY2023 | Dec 31, 2020 | ($362.95M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2019 | ($45.06M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($48.13M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2017 | ($67.33M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($26.50M) | Apr 2, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $626.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $626.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $626.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $626.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $626.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $626.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.50B) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.44B) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.36B) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.30B) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($1.19B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.37B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($841.40M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($824.41M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($788.62M) | Apr 2, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.18M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.97M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $15.17M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $9.98M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $372.0K | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $22.22M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $117.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $6.87M | Apr 2, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.04M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $62.68M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $40.79M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.53M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $32.40M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $14.77M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $12.72M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $16.80M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $31.43M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $31.71M | Apr 17, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2015 | Dec 31, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Sep 30, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Jun 30, 2015 | 0 | Mar 16, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2015 | Dec 31, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Sep 30, 2015 | 0 | Mar 16, 2016 |
| FY2015 | Jun 30, 2015 | 0 | Mar 16, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.56B | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 1.33B | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.18B | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.07B | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 948.40M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 829.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 614.30M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 523.20M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 328.90M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | 157.00M | Apr 17, 2018 |